TGFB1 and Alzheimer disease: Our present results support this fact and provide further evidence in vivo, suggesting that TGF-β1 reduction of Aβ1–42-induced upregulation of inflammatory mediators and down-regulation of neurotrophic factors may be a mechanism underlying its neuroprotection in AD.